Table 4.
Studies reporting mean (SD) percentage change in blood–lipid parameters or mean (SD) blood–lipid parameters after 52 weeks of RLX treatment
| Authors | Therapy | Total cholesterol % or mg/dL |
Triglycerides % or mg/dL |
HDL-cholesterol % or mg/dL |
LDL-cholesterol % or mg/dL |
|---|---|---|---|---|---|
| Randomized controlled trials | |||||
| Morii et al35 | RLX RLX (120 mg/day) |
NR (NR)*,a NR (NR)*,a |
NR (NR) NR (NR) |
NR (NR) NR (NR) |
NR (NR)*,a NR (NR)*,a |
| Iwamoto et al31 | RLX ALN |
−3.9 (NR)** −2.1 (NR) |
+7.4 (NR) −3.4 (NR) |
+5.1 (NR) −0.4 (NR) |
−7.7 (NR)*** +0.4 (NR) |
| Majima et al33 | RLX RLX + ALF |
202 (39), 184 (30)** 210 (29), 199 (28)* |
133 (74), 125 (58) 144 (58), 124 (72) |
57 (14), 53 (11) 57 (15), 56 (15) |
119 (38), 106 (24) 125 (30), 118 (27) |
| Hayashi et al34 | RLX HRT Control |
NR (NR), NR (NR) NR (NR), NR (NR) NR (NR), NR (NR) |
95 (24), 86 (11) 96 (25), 97 (18) 97 (21), 95 (21) |
56 (6), 64 (7)* 57 (5), 56 (8) 57 (5), 56 (6) |
113 (14), 102 (15) 112 (11), 114 (13) 119 (11), 125 (9) |
| Observational studies | |||||
| Majima et al36 | RLX | 204 (32), 192 (31)** | 123 (66), 122 (63) | 55 (13), 54 (11) | 125 (33), 113 (27)* |
Notes:
*
P<0.05,
**
P<0.01, and
***
P<0.001 indicate significant differences from baseline;
a
statistical significance is for differences between placebo and RLX groups at week 52.
Abbreviations: ALF, alfacalcidol; ALN, alendronate; HDL, high-density lipoprotein; HRT, hormone-replacement therapy; LDL, low-density lipoprotein; NR, not reported; RLX, raloxifene 60 mg/day; SD, standard deviation.